"Superhuman" AI could transform medicine, Zocdoc CEO says
The next stage of medical technology could incorporate "superhuman" augmentative artificial intelligence, Zocdoc CEO and founder Oliver Kharraz said Wednesday at Axios' Future of Health Summit in D.C.
Why it matters: Artificial intelligence can replace or supplement many of the functions within medicine, AI proponents argue.
Zocdoc started as a clearinghouse for patients to access providers, Kharraz said. Now, it boosts technology to make appointments more efficient.
"There's a really amazing journey of productivity ahead of us," he told Axios' Tina Reed.
Zoom in: Examples for future AI use cases in medicine could include high-level translation or predicting a patients' no-show likelihood.
As of now, though, "there's thousands and thousands of edge cases that you need to teach individually," Kharraz said.
State of play: The applications of artificial intelligence in health care could improve the quality of patient care and trim costly waste, Axios' Caitlin Owens previously reported.
For example, AI within biotech could discover more drugs, speed up the development process and better match drugs to patients.
It can also improve diagnostics, reduce providers' paperwork and streamline billing processes.
Driving the news: Zocdoc this month launched an AI phone assistant chatbot intended to limit hold times and book appointments. It can answer unlimited calls concurrently and "instinctively" route them.
"Free your staff to focus on care — not the phones," the Zocdoc website said.
The chatbot is autonomous and does not require human supervision. It needed to be trained in cadence adjustment and utterance detection to appropriately speak with patients in different parts of the country.
"It can pick up the phone and have a natural conversation with a patient to figure out what they need," Kharraz said.
Flashback: Kharraz in 2023 told Axios he wanted Zocdoc to be the "connective tissue of health care."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
16 hours ago
- Axios
Stop & Shop will stop offering discounted food on Flashfood app
Flashfood, the app that brings you discounted groceries, won't be available at Stop & Shop after next week. Why it matters: Shoppers will no longer be able to order a box full of vegetables or fruit for a few dollars and bypass the lines to pick them up. Driving the news: Stop & Shop will stop offering items on the Flashfood app after June 23, both companies confirmed. Stop & Shop cited low sales volume and an interest in serving shoppers who don't order through the app. What they're saying: "We want to make it easier for our customers to purchase discounted products nearing their Best Buy date," a Stop & Shop spokesperson said in a statement. Zoom in: Stop & Shop says it will now offer the items that were marked down on the Flashfood app in their aisles with "manager's special" discounts. "This shift will make it more convenient for all our customers — especially those who aren't digitally engaged — to easily purchase discounted items, which will be marked with bright yellow stickers," Stop & Shop said. The other side: "While we're incredibly disappointed in Stop & Shop's decision and valued their partnership, particularly during this time of high cost pressures on Americans, we are rapidly scaling our footprint in North America and remain committed to our mission to feed families," a Flashfood spokesperson said in a statement to Axios. "We see overwhelming consumer demand for affordable groceries, and want to ensure these customers that we are actively working to add new retailers."
Axios
17 hours ago
- Axios
Amid backlash, Tesla remained resilient in Texas
Even as Tesla deliveries plunged nationally this year amid Elon Musk's very visible (if short-lived) alliance with President Trump, there was at least one state where Tesla registrations were up: Texas. Why it matters: The registration data, obtained by Axios through public information requests, indicates loyalty to the brand in its home base, including Texas' large urban and suburban counties. The depth of conservatives' enthusiasm for Musk's automobiles now faces a major test amid the absolute meltdown last week between the Tesla CEO and the president. By the numbers: Texans registered 12,918 new Teslas in the first three months of 2025, a period when Musk, who contributed more than $250 million to a pro-Trump super PAC during the 2024 election campaign, was enmeshed in the Trump administration as the overseer of DOGE, the president's cost-cutting initiative. Over the same period in 2024, Texans registered 10,679 Teslas. That's a 21% increase year over year. The intrigue: The spike in Texas registrations came as Tesla was flailing elsewhere. Tesla's vehicle deliveries plunged 13% globally in the first quarter of 2025 (336,681 electric vehicles) compared with Q1 2024 (386,810). Tesla vehicles were torched at showrooms and the brand's reputation cratered. Zoom in: Tesla saw year-over-year improvements in its sales in some of the most populous Texas counties. In Travis County, new Tesla registrations grew from 1,369 in the first quarter of 2024 to 1,424 during the first quarter of 2025. In Harris County, they grew from 1,526 to 1,837 during the same period. Tesla registration grew from 1,316 to 1,546 in Collin County and from 990 to 1,146 in Dallas County. In Bexar County, registrations grew from 631 to 664. What they're saying:"It's homegrown pride," is how Matt Holm, president and founder of the Tesla Owners Club of Austin, explains the car company's resilience to Axios. "And regardless of all the drama going on these days, people can differentiate between the product and everything else going on, and it's just a great product." "Elon has absolutely and irreversibly blown up bridges to some potential customers," says Alexander Edwards, president of California-based research firm Strategic Vision, which has long surveyed the motivations of car buyers. "People who bought Teslas for environmental friendliness, that's pretty much gone," Edwards tells Axios. Yes, but: The company had been enjoying an increasingly positive reputation among more conservative consumers. Musk was viewed favorably by 80% of Texas Republicans polled by the Texas Politics Project in April — and unfavorably by 83% of Democrats. In what now feels like a political lifetime ago, Trump himself even promoted Teslas by promising to buy one in support of Musk earlier this year. "In some pockets, like Austin, you have that tech group that loves what Tesla has to offer, can do some mental gymnastics about Musk, and looks at Rivian and says that's not what I want or might be priced out," Edwards says. Between the lines:"Being in the state of Texas, you're naturally conditioned to think you're better than everyone else in the U.S. And when you buy a Tesla" — a status symbol — "that's what you're saying. It doesn't surprise me that there's an increase in sales" in Texas, Edwards says. Plus: Tesla's resilience in Texas could have practical reasons as well, Edwards says. Texas homes — as opposed to, say, apartments in cities on the East Coast — are more likely to have a garage to charge a car in, he adds. What's next: Musk said late last month that Tesla was experiencing a "major rebound in demand" — without providing specifics. But that was before things went absolutely haywire with Trump and Tesla stock took a bath last week.
Axios
18 hours ago
- Axios
Cancer research foundation to start seeding startups
Andy Rachleff is funding startups again, more than two decades after stepping down as a founding partner of legendary venture capital firm Benchmark. Why it matters: His new mission is curing cancers instead of generating profits for limited partners. Driving the news: Rachleff tells Axios that he's spearheading a new investment program for the Damon Runyon Cancer Research Foundation, where he chairs the board. It's called InVEST and will automatically provide $50,000 equity checks to any Damon Runyon-sponsored scientists who secure at least $500,000 in seed funding for their startups. For the scientists, it's a way to prove to venture firms that they're "fundable." For Damon Runyan, it's a way to create a philanthropic flywheel — as its alumni have founded such companies as Moderna, Juno Therapeutics, Beam Therapeutics, and Arbor Biotechnologies. Zoom in: Damon Runyan focuses exclusively on young scientists, or at least scientists who are relatively early in their careers. Rachleff and CEO Yung Lie argue that most major scientific breakthroughs come from this cohort, but that most funding goes to older colleagues. "The average age where people get their first individual NIH grant is over 40, but the average age of a Nobel Laureate in medicine is just 36 at the time they conceive of their breakthrough," Rachelff explains. By the numbers: Damon Runyan backs around 70 new scientists per year, has 1,400 alumni, and spins out between 10 and 20 startups per year. It had initially considered creating some sort of investment program whereby the startups would pay royalties but decided that could impede growth. All investments will come from the foundation's endowment.
